Hledání článků
Filtry
Demoulin N, Regemorter E, Dahan K, et al. Severe parenteral phenotype associates with hypertension in children with ADPKD. Pediatr Nephrol 2023;10. doi: 10.1007/s00467‑022‑05870‑1. Online ahead of print.
Jayne D, Rovin B, Mysler F, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 2022;81:496–506.
Přístrojová perfuze a terapeutická hypotermie ke zlepšení funkce ledvinného štěpu od zemřelého dárce
Malinoski D, Saunders C, Swain S, et al. Hypothermia or Machine Perfusion in Kidney Donors. N Engl J Med 2023;388:418–426.
Hellmich B, Sanchez‑Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA‑associated vasculitis: 2022 update. Ann Rheum Dis 2023 Mar 16:ard‑2022‑223764. doi: 10.1136/ard‑2022‑223764.
Pereira LA, Meng C, Gonc MA, et al. Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet. Nefrologia 2022, https://doi.org/10.1016/j.nefroe.2022.11.014
Barratt J, Lafayette R, Kristensen J, et al.; for the NefIgArd Trial Investigators. Results from part A of the multi‑center, double‑blind, randomized, placebo‑controlled NefIgArd trial, which evaluated targeted‑release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 2023;103:391–402.
Pichitporn W, Kanjanabuch T, Phannajit J, et al. Efficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. Am J Kidney Dis 2022;80:580.e1–588.e1.
Floyd L, Bate S, Hadi Kafagi A, et al. Risk stratification to predict renal survival in anti‑glomerular basement membrane disease. J Am Soc Nephrol 2023;34:505–514.
Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS 4 trial: post hoc analysis of an open label, randomised, phase 3 trial.
Lancet Diabetes Endocrinol 2022;10:774–785.